公众号 / 文章呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19相关ARDS溶栓药物的药理学考量

Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS.
PubMed 文献 · J Intensive Care · 2022-07-30
一句话结论综述认为,吸入或静脉溶栓药似乎可作为COVID-19相关重度ARDS的挽救治疗,通过迅速减轻肺损伤起效;在无禁忌证的稳定患者中,溶栓药似乎是颇具吸引力的选择。

本文是一篇综述,聚焦COVID-19相关ARDS中肺血管内凝血(PIC)的发生机制、溶栓药物在ARDS中的历史应用,以及溶栓治疗的药理学考量、可能获益与陷阱。文章指出,SARS-CoV-2可同时累及多器官,炎症介质过度产生、细胞与体液免疫反应加剧及凝血病(如PIC)参与细胞损伤;鉴于COVID-19中多发微血栓形成,溶栓药物似乎可发挥作用。结论认为,吸入或静脉给予溶栓药似乎可通过迅速减轻肺损伤,作为COVID-19相关重度ARDS的挽救治疗;在无禁忌证的稳定患者中,溶栓药似乎是颇具吸引力的选择。

要点

  • COVID-19相关ARDS中,炎症介质过度产生、免疫反应加剧及凝血病(如PIC)参与细胞损伤,并伴多发微血栓形成。
  • 溶栓药在COVID-19相关ARDS中的确切作用尚不明确,抗凝之外的角色有待厘清。
  • 吸入或静脉给予溶栓药似乎可通过迅速减轻肺损伤,作为COVID-19相关重度ARDS的挽救治疗。
  • 基于COVID-19相关ARDS的发病机制与溶栓药作用机制,溶栓药在无禁忌证的稳定患者中似乎是颇具吸引力的选择。

适用人群与场景

  • COVID-19相关急性呼吸窘迫综合征(ARDS)患者,尤其是重度ARDS。
  • 结论中提及的无禁忌证的稳定患者。

处置流程与药物剂量

  • 吸入或静脉给予溶栓药,似乎可作为COVID-19相关重度ARDS的挽救治疗,通过迅速减轻肺损伤起效。
  • 溶栓药在无禁忌证的稳定患者中似乎是颇具吸引力的选择。

研究设计与关键结果

  • 本文为综述,总结COVID-19相关肺血管内凝血(PIC)的机制、溶栓药物在ARDS中的历史应用,以及溶栓治疗的药理学考量、可能获益与陷阱。
  • SARS-CoV-2可同时累及多个器官,严重程度从轻度到危重不等;炎症介质过度产生、细胞与体液免疫反应加剧及凝血病(如PIC)参与细胞损伤。
  • 鉴于COVID-19的病理生理及多发微血栓形成,溶栓药物似乎在疾病管理中发挥作用;但抗凝之外,溶栓药在COVID-19相关ARDS管理中的确切作用尚不明确。
  • 结论认为,吸入或静脉给予溶栓药似乎可通过迅速减轻肺损伤,作为COVID-19相关重度ARDS的挽救治疗;基于发病机制与药物作用机制,溶栓药在无禁忌证的稳定患者中似乎是颇具吸引力的选择。

证据类型、等级与局限

  • 证据类型:综述。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,吸入或静脉给予溶栓药似乎可作为COVID-19相关重度ARDS的挽救治疗,通过迅速减轻肺损伤起效。
  • 作者认为,基于COVID-19相关ARDS的发病机制与溶栓药作用机制,溶栓药在无禁忌证的稳定患者中似乎是颇具吸引力的选择。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In late 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which is responsible for coronavirus disease (COVID-19), was identified as the new pathogen to lead pneumonia in Wuhan, China, which has spread all over the world and developed into a pandemic. Despite the over 1 year of pandemic, due to the lack of an effective treatment plan, the morbidity and mortality of COVID-19 remains high. Efforts are underway to find the optimal management for this viral disease.

MAIN BODY: SARS-CoV-2 could simultaneously affect multiple organs with variable degrees of severity, from mild to critical disease. Overproduction of pro-inflammatory mediators, exacerbated cellular and humoral immune responses, and coagulopathy such as Pulmonary Intravascular Coagulopathy (PIC) contributes to cell injuries. Considering the pathophysiology of the disease and multiple microthrombi developments in COVID-19, thrombolytic medications seem to play a role in the management of the disease. Beyond the anticoagulation, the exact role of thrombolytic medications in the management of patients with COVID-19-associated acute respiratory distress syndrome (ARDS) is not explicit. This review focuses on current progress in underlying mechanisms of COVID-19-associated pulmonary intravascular coagulopathy, the historical use of thrombolytic drugs in the management of ARDS, and pharmacotherapy considerations of thrombolytic therapy, their possible benefits, and pitfalls in COVID-19-associated ARDS.

CONCLUSIONS: Inhaled or intravenous administration of thrombolytics appears to be a salvage therapy for severe ARDS associated with COVID-19 by prompt attenuation of lung injury. Considering the pathogenesis of COVID-19-related ARDS and mechanism of action of thrombolytic agents, thrombolytics appear attractive options in stable patients without contraindications.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Amini S, Rezabakhsh A, Hashemi J, et al. Pharmacotherapy consideration of thrombolytic medications in COVID-19-associated ARDS. J Intensive Care. 2022. PMID: 35908022. doi:10.1186/s40560-022-00625-4

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。